Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction

Rohan Samson, MD; Abhishek Jaiswal, MD; Pierre V. Ennezat, MD; Mark Cassidy, MD; Thierry H. Le Jemtel, MD

Over the past 2 decades, the syndrome of heart failure with preserved ejection fraction (HFpEF) received a lot of attention.1–19 However, little therapeutic progress was made.20–27 Among the issues that may account for the modest therapeutic progress, one appears to be overwhelming: HFpEF is not a well-defined clinical entity: It is an amalgam of cardiovascular, metabolic, renal, and geriatric conditions.28,29 Patients diagnosed with HFpEF currently, were until few years ago managed for systemic hypertension, coronary artery disease (CAD), obesity, renal impairment, pulmonary hypertension (PH), or age-related deconditioning.

A rational approach for improving the outcome of patients with HFpEF may be to treat patients according to the conditions that led them to seek medical attention. As noted by others, a phenotype-oriented approach to heart failure (HF) and, in particular, to HFpEF is needed.29–31 The diagnosis of HFpEF rests on the presence of signs and symptoms of HF and a normal left ventricular (LV) ejection fraction. Left ventricular diastolic dysfunction (LVDD) does not establish the presence of HF and may bias toward an exclusive role for the heart in the pathogenesis of HFpEF.32,33

As a whole, HFpEF has been extensively reviewed.1–19 The present review focuses on 4 commonly encountered clinical phenotypes of HFpEF and their comorbid conditions (Figure). Therapeutic implications are discussed.

Aging Phenotype
Pathogenesis
Hypertension and age are major risk factors for HFpEF.34,35 Community-based studies have highlighted the high incidence of HFpEF in the elderly and very elderly (≥80 years of age).36–39 Age-related systemic changes contribute to myocardial molecular dysfunction and eventually to cardiac structural alterations and HFpEF.40 Age-related changes comprise neurohormonal dysregulation (angiotensin II, endothelin) and a proinflammatory state (tumor necrosis factor alpha, reactive oxygen species, and monocyte chemotactant protein). Age also affects the vasculature.41,42 The major effect of age on the vasculature is systolic hypertension with widening of the pulse pressure that results from age-related increase in arterial stiffness and early wave reflections.43,44 Arterial stiffening and early wave reflections are steady vascular features in HFpEF.45–52 In the proximal arterial tree, vascular smooth cell loss of elastin increases systolic arterial pressure by lessening the “windkessel” effect.44,45,53 In the distal arterial tree, several pathways contribute to early wave reflections.44,45,53 In middle-aged and elderly subjects, when the aortic lumen is no longer enlarging, arterial stiffness clearly predicts blood pressure progression.54 Neuroendocrine activation (angiotensin II, aldosterone, and endothelin), metabolic alterations (insulin, hyperglycemia, and advanced glycation products), and inflammation (cytokines, oxidative stress, and nuclear factor kappa B) mediate collagen breakdown, cross-linking, and glycation that promote early wave reflections by increasing peripheral arterial resistances.55,56 Arterial stiffness is routinely assessed by carotid to femoral pulse wave velocity.57–59 Common comorbid conditions in HFpEF (obesity, hypertension, diabetes, obstructive sleep apnea [OSA], anemia, and renal impairment) are independently associated with increased arterial stiffness.58 However, arterial stiffness is consistently greater in HFpEF patients than in those who, with similar comorbidities, do not have HF.51,60,61 Thus, age-related increase in arterial stiffness is an important determinant of HFpEF.62,63

By increasing systolic arterial pressure, arterial stiffening imposes an excessive load on the heart that leads to LVDD, ventricular-vascular uncoupling, and afterload mismatch.46,64 Aging greatly affects the efficiency of ventricular-vascular coupling during exercise.65 Of relevance to the preponderance of women in HFpEF, reduced efficiency of ventricular-vascular coupling with age is related to increased effective arterial elastance in women, whereas it relates to increased ventricular systolic elastance in men.65 With time, LVDD worsens and patients develop shortness of breath and fatigue.66–69

From the Tulane University Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA (R.S., A.J., M.C., T.H.L.J.); and Department of Cardiology, Centre Hospitalier Universitaire de Grenoble, Grenoble Cedex 09, France (P.V.E.).

Correspondence to: Thierry H. Le Jemtel, MD, Tulane University School of Medicine, 1430 Tulane Ave, SL-48, New Orleans, LA 70112. E-mail: lejemtel@tulane.edu

J Am Heart Assoc. 2016;5:e002477 doi: 10.1161/JAHA.115.002477.
© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Symptoms correlate with LVDD severity that, in turn, results from progressive arterial stiffening.\textsuperscript{70}

A novel paradigm in HFpEF associates comorbid conditions to an inflammatory state that increases LV stiffness and promotes HF.\textsuperscript{71} The cellular and molecular mechanisms that lead from systemic inflammation to myocardial fibrosis (reduced nitric oxide bioactivity, cyclic guanosine monophosphate content, and protein kinase G) also promote arterial stiffening, with the endothelium being an essential component of vascular homeostasis.\textsuperscript{72-75} The novel paradigm broadens our understanding of the mechanisms that underlie progression of LV remodeling in HFpEF with age-related increase in arterial stiffness as the likely trigger of LV remodeling.

**Therapeutic Implications**

Lowering neurohormonal activation has unexpectedly failed to improve clinical outcome in large, placebo-controlled, randomized HFpEF trials.\textsuperscript{20-24} Diagnostic uncertainties may partially account for the lack of therapeutic benefit.\textsuperscript{29,76,77} However, the consistently neutral findings of these trials strongly suggest that neurohormonal modulation may not be beneficial in patients with HFpEF. In contrast to the well-established effect of neurohormonal modulation on LV remodeling in heart failure with reduced ejection fraction (HFrEF), it may have only modest effect on LV remodeling in HFpEF, with LV mass decreasing by \(\leq 10\%\) in hypertensive patients.\textsuperscript{78,79} Whether a modest reduction in LV mass reliably improves LVDD is unclear.

Reduced LV compliance and right ventricular (RV) remodeling are strong predictors of a poor outcome in HFpEF.\textsuperscript{80,81} Therapeutic trials in HFpEF have shown a greater prevalence of fatal outcome and HF hospitalizations than hypertension trials in elderly patients without HF.\textsuperscript{82} Although clinical events are clearly more prevalent when HFpEF is associated with severely reduced LV compliance and increased RV wall thickness, HFpEF may no longer be amenable to therapy at that stage. The lack of therapeutic success in patients with HFpEF suggests that the time to intervene may be earlier at the stage of preclinical diastolic dysfunction.\textsuperscript{83} A critical prerequisite for earlier initiation of intensive antihypertensive therapy is identification of hypertensive patients who are at risk of progressing to HFpEF.

Circulating biomarkers and direct measurement of arterial stiffness may identify hypertensive patients at risk for HFpEF. Cardiac troponin T, alone or in combination with N-terminal fragment of the prohormone of B-type natriuretic peptide (NT-proBNP), and products of collagen metabolism have been evaluated for identification of hypertensive patients at risk for HF.\textsuperscript{84-87}

Baseline high-sensitivity troponin and changes in troponin were found to be associated with incident HF or cardiovascular death in community-dwelling older adults without known HF.\textsuperscript{84} Elevation of troponin and NT-proBNP above the age- and sex-specific 75th percentile of the population identifies a malignant subphenotype of left ventricular hypertrophy (LVH) with high risk for progression to HF and cardiovascular death.\textsuperscript{85} An increase in plasma troponin and NT-proBNP by >50\% in patients with low baseline levels identifies patients at risk for incident HF and cardiovascular death in the Cardiovascular Health Study.\textsuperscript{84}

Plasma tissue inhibitor of matrix metalloproteinase type 1 (TIMP-1) is elevated in patients with LVDD and correlates with markers of LV filling in patients with untreated hypertension.\textsuperscript{88} Circulating levels of carboxy-terminal propeptide of procollagen type 1, carboxy terminal telopeptide of procollagen-1, amino-terminal peptide of procollagen type III, matrix metalloproteinase (MMP)-2, and MMP-9 levels are greater in hypertensive patients with LVDD than in those without LVDD.\textsuperscript{89} In the Cardiovascular Health Study, the same makers of increased collagen turnover were elevated in patients with hypertension and LVDD.\textsuperscript{90} In 2011, a panel of 17 biomarkers, including NT-proBNP, cardioprophin, osteopontin, and soluble receptor for advanced glycation products, in addition to...
markers of collagen metabolism, was found to have a greater discriminative value for identification of LVH and HF in patients with hypertension than any single marker. More recently, a meta-analysis concluded that circulating levels of TIMP-1, MMP-2, and MMP-9 identify hypertensive patients with LV remodeling, with circulating level of TIMP-1 being the most specific for LVDD. In summary, serial determinations of circulating markers of collagen synthesis/degradation may allow identification of patients who, with preclinical diastolic dysfunction, are at risk for HF.

An alternative approach for identification of hypertensive patients with preclinical diastolic dysfunction or at risk for HF is to monitor arterial stiffness by serially measuring pulse wave velocity. Recent European Society of Hypertension and Cardiology guidelines have endorsed this approach for detection of subclinical target organ damage. Measurement of pulse wave velocity may be technically difficult in markedly obese patients with abundant adipose tissue over the groin. Arterial stiffness may be indirectly monitored by measuring circulating galectin-3 given that it correlates with pulse wave velocity after adjustments for relevant variables. Circulating levels of galectin-3 do not appear to predict outcome in HFpEF after adjustment for age and renal function.

Identification of patients with preclinical diastolic dysfunction or at risk for HF is needed for the design and conduct of therapeutic interventions that may prevent/delay the development of HFpEF in hypertensive patients. Elderly hypertensive patients with preclinical diastolic dysfunction or at risk for HF may benefit from more-intensive antihypertensive therapy than recommended in the latest guidelines. A systolic blood pressure target goal of less than 120 mm Hg reduced the risk of incipient heart failure by 38%, as compared to the standard goal of less than 140 mm Hg, in the Systolic Blood Pressure Intervention Trial (SPRINT) trial.

Obesity Phenotype

Pathogenesis

North American urban HFpEF registries have highlighted a distinct subset of HFpEF patients. The subset consists of African American women with hypertension and obesity who, when diagnosed with HFpEF, are on average 10 to 15 years younger than their mainstream counterparts. Whereas the HFpEF obesity association was initially reported in African American women, it is not specific to sex or ethnicity. Obesity was reported in 34% of the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) trial and in 40% of patients who, undergoing coronary angiography at the Mayo clinic, were found to have LV remodeling and diastolic dysfunction without obstructive epicardial CAD. Sex-related increase in LVH and proximal aortic stiffness with altered ventricular-arterial coupling partly accounts for the preponderance of women in HFpEF.

An elevated body mass index (BMI; kg/m²) is a recognized risk factor for new-onset HFrEF and HFpEF. Obesity has been associated with LVH and incipient LV dysfunction. In the Dallas Heart Study, central adiposity was linked to concentric LVH and lower body obesity to eccentric LVH. Measurement of waist circumference and waist-hip ratio may be preferred to BMI when evaluating patients with HFpEF and increased body weight. Besides age and hypertension, obesity and especially central obesity is a major determinant of arterial stiffness.

Increased arterial stiffness in this mouse model is related to sympathetic nervous system activation, reduced nitric oxide bioactivity, and inflammation. Voluntary weight loss with a low-calorie diet for 12 weeks is associated with a decrease in arterial stiffness in overweight/obese, middle-aged, and elderly subjects. The decrease in arterial stiffness correlates with a reduction in total body weight and abdominal obesity. Aerobic exercise training and a low-calorie diet for 7 weeks reduces arterial stiffness to a greater extent than diet alone in morbidly obese subjects. Two observations are relevant to obesity in HFpEF: (1) Obesity correlates with arterial stiffness in women and not in men. Not unexpectedly, obesity and arterial stiffness did not correlate in an HFpEF population with nearly as many men as women. The duration of morbid obesity affects the LV response to weight loss.

In addition to increasing arterial stiffness, obesity is associated with 4-fold greater prevalence of OSA, which contributes to the pathogenesis of HFpEF through multiple mechanisms: Sympathetic activation increases LV afterload, hypoxic pulmonary vasoconstriction reduces LV preload, oxidative stress stimulates inflammation, and hypoxia predisposes to atrial and ventricular arrhythmias.

When estimated by BMI, obesity is associated with a favorable outcome in patients with HF, a phenomenon that is referred to as the obesity paradox. However, when obesity is assessed by indices of visceral obesity, such as waist circumference and waist-hip ratio, the obesity paradox is no longer apparent. In the 4109 patients of the I-PRESERVE trial, BMI and adverse clinical events were related, with the greatest rate of adverse outcomes in the lowest and highest BMI categories. The relationship between obesity and clinical outcome has not been specifically investigated in the obesity HFpEF phenotype.

Independently from body composition, African Americans are at high risk for HFpEF. They are 2 to 3 times more
likely to develop LVH than Caucasians.\textsuperscript{138,139} African Americans remain at higher risk to develop HF than Caucasians after adjustment for many HF risk factors.\textsuperscript{140–142} In a community-based sample of middle-aged African Americans, three quarters of ambulatory patients with HF had HfpeF.\textsuperscript{143} Eighty-five percent of HfpeF patients were women. The most common comorbid conditions were hypertension and obesity in 85% and 71% of patients, respectively.\textsuperscript{143} In summary, central obesity appears to cause premature arterial stiffening and thereby to hasten the progression to HfpeF in hypertensive patients, particularly in African American women.

**Therapeutic Implications**

Obesity-induced premature arterial stiffening is a clear target of therapy in obese patients with HfpeF. Exercise training reduces arterial stiffness.\textsuperscript{144} However, obese patients may not be able to exercise at sufficient workloads to reverse vascular remodeling. Sustained and substantial weight loss is more reliably attained by bariatric surgery than by lifestyle modifications and medications.\textsuperscript{145–147} Importantly, bariatric surgery improves LV relaxation and reverses concentric LV remodeling, with a substantial reduction in LV mass.\textsuperscript{148–150} In addition to decreasing arterial stiffness and blood pressure, bariatric surgery improves/cures OSA and diabetes.\textsuperscript{151} In the absence of evidence-based data, one cannot recommend gastric bypass surgery in obese HfpeF patients. The long-term cardiovascular effects of bariatric surgery clearly need to be assessed in obese HfpeF patients.

**PH Phenotype**

**Pathogenesis**

The diagnosis and management of PH from left heart disease–group 2 PH has been extensively reviewed.\textsuperscript{152–156} Venous (postcapillary) PH, resulting from enduring elevation in left atrial (LA) pressure, is the most common cause of PH.\textsuperscript{157,158} Functional mitral regurgitation and LVDD are associated with marked LA pressure elevation. Both are major determinants of PH in patients with Hfref.\textsuperscript{159} All patients with Hfref have some degree of functional mitral regurgitation and LVDD as their condition deteriorates.\textsuperscript{9,160} However, only 60% of patients with advanced Hfref develop PH.\textsuperscript{152} Tight control of LA pressure with loop diuretic therapy, sudden death before symptomatic deterioration, or both may account for near normal pulmonary artery (PA) pressure in 40% of patients with Hfref. On the other hand, an arterial (precapillary) component contributes to PH in 25% to 30% of patients with Hfref.\textsuperscript{154,157} Impaired vascular reactivity with endothelin/nitric oxide imbalance, hypertrophy of vascular smooth muscle cells, extracellular matrix deposition, and genetic factors worsen precapillary PH in the setting of postcapillary PH.\textsuperscript{154,157} An elevated mean or diastolic transpulmonary pressure gradient (TPG) provides direct evidence of a precapillary component to group 2 PH.\textsuperscript{154,161} The beneficial effect of phosphodiesterase type 5 inhibition (PDE5-I) in Hfref provides indirect evidence of a precapillary component to group 2 PH given that PDE5-I is effective in patients with arterial PH.\textsuperscript{162–164}

The prevalence of PH is slightly greater in HfpeF than in Hfref.\textsuperscript{152} Not surprisingly, the severity of LVDD is as much a determinant of PH in HfpeF as it is in Hfref.\textsuperscript{165–167} In addition, functional mitral regurgitation attributable to mitral leaflets tenting resulting from elevated LA pressure plays a role in the pathogenesis of PH in HfpeF.\textsuperscript{168–172} The contribution of functional mitral regurgitation to PH is greater in the decompensated state, when LA pressure is markedly elevated, than in the compensated state.\textsuperscript{172} As noted in Hfref, patients with HfpeF may exhibit PA pressures that are “out of proportion” to LA pressures secondary to impaired pulmonary vascular reactivity and structural alterations that add a precapillary component to postcapillary PH.\textsuperscript{161,173} The diagnosis of group 2 PH rests on the documentation of mean PA pressure $\geq$25 mm Hg and LV filling pressure $>$15 mm Hg. Direct measurement of LV diastolic pressure by left heart catheterization provides a more reliable measurement of LV filling pressure than pulmonary capillary wedge pressure in patients with severe PH or tachycardia.\textsuperscript{157} Direct measurement of LV diastolic pressure may prevent to diagnose type II PH in a patient with type I PH.\textsuperscript{174} Because pulmonary blood flow affects the TPG, diastolic TPG (when pulmonary flow substantially decreases) may be preferred to mean TPG to evaluate intrinsic changes in the pulmonary vasculature. A diastolic TPG $<7$ mm Hg denotes isolated postcapillary PH, and a diastolic TPG $\geq 7$ mm Hg is indicative of combined pre- and postcapillary PH.\textsuperscript{175}

A caveat to the hemodynamic criteria of type II PH is that severe RV failure may result in elevated LV filling pressure attributable to ventricular interdependence with encroachment of a dilated RV into the LV.\textsuperscript{157} In such instances, inotropic therapy may decompress the RV, thereby alleviating ventricular interdependence.\textsuperscript{157} The converse caveat of type II PH hemodynamic criteria is that type II PH may be missed when in patients with intravascular depletion.\textsuperscript{176} Fluid challenge or, preferably, supine exercise during right heart catheterization may ascertain the diagnosis.\textsuperscript{176–178} Last, when PH cannot account for the severity of RV failure, transthyretin cardiac amyloidosis should be suspected.\textsuperscript{179} In summary, HfpeF is a common cause of PH. When PH is “out of proportion” to the increase in LA pressure, it may be misdiagnosed as a primary arterial PH.
Therapeutic Implications

Management of PH in HfPEF presently rests on control of fluid accumulation and enhancement of LV filling. Placebo-controlled, randomized trials of endothelin antagonist with ambrisentan and bosentan have been terminated early because of poor enrollment or led to neutral findings, respectively (ClinicalTrials.gov Identifiers: NCT00840463, NCT00820352). The placebo-controlled Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) trial randomized 216 patients with HfPEF and moderate PH to PDE5-I with sildenafil. Compared to placebo, sildenafil did not significantly improve functional capacity and clinical status. Notwithstanding that PDE5-I may have failed to improve LV function, the selection of patients with moderate PH may partly account for the neutral findings of the RELAX trial. Direct measurement of PA pressure and TPG by right heart catheterization was not required in the RELAX trial. Recently, treatment with sildenafil failed to reduce PA pressure or hemodynamic parameters in a HfPEF cohort. In contrast, a single-center, placebo-controlled, randomized trial reported significant improvements in PA pressure, RV function, and LV relaxation with sildenafil in patients with HfPEF and PH. In the absence of evidence-based data, PDE5-I cannot be recommended for the treatment of PH in HfPEF. Riociguat, a soluble guanylate cyclase stimulator that sensitizes guanylate cyclase through nitric oxide–dependent and –independent pathways, has been evaluated for the treatment of PH in HfPEF. Riociguat increases stroke volume and cardiac output without changes in pulmonary vascular resistance and TPG. The lack of US Food and Drug Administration–approved therapy makes the management of HfPEF patients with PH and particularly out of proportion PH extremely challenging. In summary, a subset of HfPEF patients seeks medical attention for PH-related symptoms. The prognosis of HfPEF patients with PH is poor because no specific therapy is presently available to alleviate the progression of PH.

CAD Phenotype

Pathogenesis

In contrast to HFrEF, where obstructive CAD is a major consideration in the evaluation and management of patients, CAD has received little attention in HfPEF. Though abnormal relaxation is the first mechanical manifestation of myocardial ischemia, acute coronary artery syndromes seldom precipitate HfPEF decompensation or present as HfPEF. The prevalence of CAD ranges from 35% to 53% in large HfPEF registries. The prevalence of CAD in HfPEF varies with the ethnic background of patients. When patients are mostly Caucasians, CAD appears to be highly prevalent and routine coronary artery angiography is recommended. Noninvasive testing fails to detect the presence of CAD in at least one third of HfPEF patients. In contrast, the prevalence of myocardial ischemia is less than 4% in a multiethnic population of patients presenting with shortness of breath and without wall motion abnormalities. Not surprisingly, patients with HfPEF and CAD experience a greater deterioration of LV function and a worse prognosis than patients with only HfPEF. However, a fatal outcome does not appear to be related to the presence of CAD in patients hospitalized for a first episode of HfPEF decompensation. Patients with HfPEF and angina are at a significantly greater risk of myocardial infarction, coronary revascularization, stroke, and death than HfPEF patients without angina. Surgical and percutaneous coronary revascularization improves clinical outcome in patients with HfPEF and symptomatic CAD. Of note, coronary revascularization does not prevent the recurrence of flash pulmonary edema in patients with CAD and preserved LV systolic function.

In addition to epicardial CAD, coronary microvascular rarefaction has been recently reported at postmortem examination of transmural LV specimens from HfPEF patients, compared to age-appropriate control patients, who underwent autopsy after a noncardiac death. Coronary microvascular rarefaction was found to correlate with the ante mortem severity of LVH and diastolic dysfunction, as assessed by Doppler echocardiography. Whether coronary microvascular rarefaction and LV dysynchrony are related in patients with HfPEF and narrow QRS has not been investigated. Microvascular dysfunction may not be limited to the myocardium given that the hyperemic response of the forearm subcutaneous microvasculature is impaired in HfPEF. In summary, when present CAD greatly affects the management and clinical course of HfPEF.

Therapeutic Implications

When HfPEF and CAD coexist, management needs to focus on CAD as well as on diuretic and antihypertensive therapy. Shortness of breath is unquestionably a cardinal symptom of HfPEF. However, when it fails to resolve with loop diuretic therapy, shortness of breath may be an angina equivalent. Focusing on HfPEF may delay stress imaging studies or coronary angiography in patients who, with HfPEF and narrow QRS has not been investigated. Microvascular dysfunction may not be limited to the myocardium given that the hyperemic response of the forearm subcutaneous microvasculature is impaired in HfPEF. In summary, when present CAD greatly affects the management and clinical course of HfPEF.

Comorbid Conditions

All phenotypes of HfPEF have in common a multitude of comorbid conditions. Rare is the HfPEF patient with...
only one comorbid condition. Atrial fibrillation, anemia, chronic obstructive pulmonary disease (COPD) and frailty are common comorbidities of the aging phenotype. OSA, diabetes, and chronic kidney disease (CKD) are more prevalent in the obesity phenotype.

The presence of multiple comorbid conditions heavily affects the clinical course in HFpEF. In an HF population of Medicare beneficiaries with a preponderance of women, comorbid conditions accounted for 45% of preventable hospitalizations. An even greater clinical burden of noncardiac comorbid conditions has been reported in a mostly male population of HFpEF patients. The risk of hospitalization is closely related to the number of comorbid conditions. The high prevalence of comorbid conditions also affects the mode of death in HFpEF patients. In contrast to the findings of large, randomized therapeutic trials, registries have reported a preponderance of noncardiac deaths in HFpEF.

Aging-Related Comorbid Conditions

Atrial Fibrillation

With hypertension as a steady background and aging as a common phenotype, atrial fibrillation (AF) is predictably a prevalent comorbid condition in HFpEF. A history of AF was present in 29% of I-PRESERVE and Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved patients. The prevalence of AF reached 44% and 51% in elderly I-PRESERVE patients with a median age of 75 and 82 years, respectively. AF is also highly prevalent in patients hospitalized for acutely decompensated HFpEF. Because of underlying diastolic dysfunction, AF may persist even after recovery of LV systolic function.

Despite some discordant findings, the presence of AF is now widely recognized to portend a poor outcome in HFpEF. LA structural remodeling that provides the reentry substrate for AF clearly differs in HFpEF and HFrEF. Increased LA stiffness and greater LA pulsatility may result in a higher AF burden in HFpEF than in HFrEF. In brief AF, a common comorbid condition of HFpEF, is particularly prevalent in the aging phenotype. AF increases hospitalizations and predicts a poor prognosis independent of the stroke risk.

Anemia

Anemia is an independent predictor of mortality in patients with HFpEF. Its prevalence is similar to that of CKD, diabetes, and COPD. Anemia is mostly prevalent in elderly women with advanced HFpEF, CKD, and diabetes. Anemia in HF has the same profile as in chronic disease with defective utilization of iron, impaired erythropoietin responsiveness, and depressed bone marrow function. Neurohormonal activation, renal dysfunction, hemodilution, and systemic inflammation contribute to the development of anemia in HFpEF. Functional iron deficiency with upregulation of myocardial transferrin receptor has been reported in the absence of anemia in HFpEF patients. The clinical implication of functional iron deficiency in HFpEF is presently unclear. It does not appear to correlate with function capacity or LV stiffness. A pooled analysis in a mixed population of HFpEF and HFrEF patients found that iron deficiency without anemia portends a worse prognosis than anemia without iron deficiency. From a therapeutic standpoint treatment with erythropoietin alpha does not improve functional capacity or reduce LV mass in elderly HFpEF patients.

COPD

In a mostly male elderly population of HFpEF, up to 45% of patients have been reported to have COPD. The overall prevalence of COPD in HFpEF is 30%. When present, COPD is an independent predictor of mortality. Its impact on mortality is greater in HFpEF than HFrEF. The link between HFpEF and COPD is incompletely understood. The proinflammatory state associated with COPD may hasten the development of myocardial fibrosis, and COPD may directly impair LV filling. In patients with atrial fibrillation, COPD hastens the development of HFpEF.

Dyspnea is the cornerstone symptom of both HFpEF and COPD. A commonly faced therapeutic challenge is to determine whether dyspnea is attributable to COPD exacerbation, HFpEF decompensation, or both in patients who, with known HFpEF and COPD, present with symptomatic deterioration. Because both conditions feed on each other, an efficient approach may be to initiate aggressive treatment of both conditions on presentation.

Frailty

The concept of frailty refers to decreased homeostatic reserves, resulting in increased vulnerability to acute stress. As a concept, frailty differs from comorbidity, which is the cooccurrence of multiple conditions. Frailty can be primary as a consequence of aging or secondary attributable to the presence of comorbidity. However, given that the stress that reveals frailty is often the deterioration of comorbidity, one cannot, in most instances, definitely differentiate primary frailty from secondary frailty. Overall, frailty is a well-recognized component of chronic conditions, with a prevalence of 60% and 40% in obstructive pulmonary and kidney diseases, respectively. The prevalence of HF-related frailty is notably greater than that of age matched in community-dwelling elders.
ranges from 20% to 74%, depending on age and criteria used to define frailty. When older than 70 years, 52% of patients with HF are frail compared to 30% when they are younger than 70 years. Frailty is more prevalent in patients with HFpEF than HFrEF given that the former patients tend to be older and have more comorbidities. AF, a common comorbidity of the aging phenotype of HFpEF, hastens development and progression of frailty. After adjustment for confounders, including comorbidities, frailty was found to be an independent predictor of visits to the emergency department and hospitalizations in ambulatory patients with HF. Frailty increased emergency visits by 92% and hospitalizations by 65%. In summary, frailty, which commonly occurs in HFpEF, may be particularly prevalent in the aging phenotype.

Obesity-Related Comorbid Conditions

OSA

The prevalence of OSA ranges from 40% to 62% in obese patients with HFpEF compared to 10% in nonobese HFpEF patients. Independently from hypertension and obesity, OSA impairs LV diastolic function, begets LVH, and thus may hasten HFpEF progression. Repetitive sleep arousals and hypoxic episodes heighten sympathetic activity and promote endothelial dysfunction, systemic inflammation, and arterial stiffness that may further increase blood pressure and accelerate atherosclerosis progression.

Continuous positive airway pressure (CPAP) is the present standard of care for OSA. In patients with HFrEF, CPAP improves functional class and reduces sympathetic activity, heart rate, and blood pressure. Furthermore, OSA therapy is associated with a trend toward improvement in survival. In contrast to HFrEF, CPAP therapy has not been extensively evaluated in HFpEF. Adherence to CPAP therapy is known to decrease systolic blood pressure, reduce arterial stiffness, and improve LV diastolic function in patients with hypertension and OSA. The effects of CPAP on morbidity and mortality have not been evaluated in large, randomized trials in patients with HFpEF. Nevertheless, because of the beneficial effect of CPAP therapy in hypertension, obese patients with HFpEF should undergo a sleep study to establish the presence of OSA and, if indicated, be initiated on CPAP therapy.

Diabetes

The prevalence of diabetes averages 45% in HFpEF. It was as high as 61% in the Urban Baltimore Community Registry. Diabetes hastens the transition from preclinical diastolic dysfunction to HFpEF and is associated with a nearly 2-fold increase in mortality and morbidity in HFpEF. Insulin resistance and hyperglycemia affect HFpEF patients through multiple mechanisms. They include increased free fatty acid concentration, mitochondrial dysfunction, abnormal calcium homeostasis, oxidative stress, and advanced glycation endproducts. Besides its detrimental effect on myocardial relaxation and LV ventricular stiffness, diabetes increases arterial stiffness and accelerates wave reflections. Pulse pressure is greater and renal dysfunction is more prevalent in diabetic than nondiabetic patients. Diabetes and obesity are linked; obesity compounds diabetes’ effects on the myocardium and arterial wall. Aerobic capacity and walking distance were recently reported to be lower in diabetic than nondiabetic HFpEF patients. A similar observation had been previously reported in HFrEF patients. As hypothesized in HFrEF patients with diabetes, skeletal muscle metabolic alterations are likely to contribute to the lower aerobic capacity of diabetic HFpEF patients.

From a therapeutic standpoint, a joint endocrine-HF clinic is an attractive approach given that diabetes is common in HFpEF patients who require frequent adjustments of their hypoglycemic regimen. Mitochondria-targeted antioxidants may lower oxidative stress and improve LV diastolic function.

CKD

Renal dysfunction is common in HFpEF patients and especially prevalent in elderly obese/diabetic patients with hypertension. Overall, renal dysfunction is present in 30% to 60% of patients with HFpEF. The prevalence of renal dysfunction is greater when defined by estimated glomerular filtration rate (eGFR) <60 mL/min/m² and high urinary albumin creatinine ratio than by eGFR alone. Low eGFR and high urinary albumin creatinine ratio are associated with cardiac remodeling and subtle LV systolic dysfunction in HFpEF. A high urinary albumin creatinine ratio alone has been associated with RV/LV remodeling and LV longitudinal systolic dysfunction in HFpEF. Renal dysfunction on presentation is associated with a poor prognosis in patients who are hospitalized for a first decompensation of HFpEF. Patients with worsening renal function during the index hospitalization have an even poorer prognosis. In contrast to HFrEF, worsening renal function after angiotensin receptor blockade is associated with a poor outcome in HFpEF. Renal dysfunction increases the risk of adverse events during long-term renin-angiotensin system inhibition in HFpEF patients. Renal dysfunction may lead to loop diuretic resistance and the need for ultrafiltration. Besides being associated with a poor prognosis, renal dysfunction complicates the management of patients who, with HFpEF, require a tight control of fluid accumulation.
Future Directions

The large, all-inclusive, randomized, placebo-controlled therapeutic trials approach that led to great therapeutic progress in HFrEF has not worked so far in HFpEF.\textsuperscript{20–27} Such discrepancy is, in part, attributable to overt differences in the pathogenesis and progression of HFpEF and HFrEF. In that regard, marked clinical heterogeneity and multiple comorbidities argue in favor of a phenotyping approach to HFpEF.

Preliminary data derived from the I-PRESERVE trial and validated in the CHARM-Preserved trial suggest that latent class analysis can identify 6 subgroups of patients with HFpEF from 11 clinical variables.\textsuperscript{219} These 6 subgroups exhibited significant differences in event-free survival and, possibly, treatment response. Identification of HFpEF subgroups with different outcomes may help select specific endpoints and interventions that, in turn, will improve the likelihood of a positive treatment response. Whether latent class analysis is used to identify HFpEF subgroups or few clinical variables help define HFpEF phenotypes, delineation of the HFpEF syndrome into clinical cohorts may resolve the current therapeutic conundrum.

Conclusion

Any attempt at clinical classification is, by essence, arbitrary. Nevertheless, defining clinical phenotypes in HFpEF may help the management of patients with HFpEF and possibly lead to therapeutic progress. Elderly patients with long-standing hypertension and HFpEF are likely to benefit from a different therapeutic approach than middle-aged obese HFpEF patients. Patients who seek medical attention for PH-related symptoms are clearly in need of specific therapy. When HFpEF and CAD coexist, great attention needs to be given to both conditions. Last, HFpEF is associated with a multitude of comorbid conditions that require specific therapies.

Disclosures

None.

References

1. Cohn JN, Johnson G. Heart failure with normal ejection fraction, the V-HeFT study. Circulation. 1990;81(suppl III):III-48–III-53.
2. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1656–1674.
3. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part I diagnosis, prognosis and measurements of diastolic function. Circulation. 2002;105:1387–1393.
4. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II. Causal mechanisms and treatment. Circulation. 2002;105:1503–1508.
5. Kitzman DL, Little WC, Brubaker PH, Anderson RT, Hundley GW, Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288:2144–2150.
6. Aurigemma GP, Gaasch WH. Diastolic heart failure. N Engl J Med. 2004;351:1097–1105.
7. Kass DA, Jean GF, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res. 2004;94:1533–1542.
8. Zile MR, Beecu C, Gaasch WH. Diastolic heart failure abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953–1959.
9. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic heart ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202.
10. Burkhof D, Maurer MS, Packer M. Heart failure with a normal ejection fraction. Is it really a disorder of diastolic function? Circulation. 2003;107:656–658.
11. Maurer MS, King DL, El-Koury Rumbarger L, Packer M, Burkhof D. Left heart failure with a normal ejection fraction: identification of different pathophysiological mechanisms. J Card Fail. 2005;11:177–187.
12. Lester SJ, Tajik AJ, Nishimura RA, Oh JK, Kandheria BK, Seward JB. Unlocking the mysteries of diastolic dysfunction. J Am Coll Cardiol. 2008;51:679–689.
13. Wang GW, Naghuf SF. Current perspectives on cardiac function in patients with diastolic heart failure. Circulation. 2009;119:3044–3046.
14. De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation. 2011;123:1996–2004.
15. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis and treatment. Eur Heart J. 2011;32:670–679.
16. Ferrari R, Böh m M, Cleland JG, Paulus WJ, Pieske B, R apezzi C, Tavazzi L. Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail. 2015;17:665–671.
17. Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res. 2014;115:79–96.
18. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123:2006–2013.
19. Jeong EM, Dudley SC Jr. Diastolic dysfunction. Circ J. 2015;79:470–477.
20. Yusuf S, Pfeffer MA, Swedeng K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergen J. Effects of candesartan on patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–781.
21. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie RS, Zile MR, Anderson S, Donovan M, Iverson E, Stieger C, Plotzynska A, Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–2467.
22. Cleland JG, Tendera M, Adams J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345.
23. Kitzman DW, Hundley GW, Brubaker PH, Morgan T, Moore JB, Stewart KP, Little WC. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail. 2010;3:477–485.
24. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Caggiati A, Clussell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishihi T, Shah SJ, Solomon SD, Switzer NK, Yang S, McKinlay SM, TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392.
25. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Caggiati A, Clussell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishihi T, Shah SJ, Solomon SD, Switzer NK, Yang S, McKinlay SM, TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392.
26. Ahmad A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF Jr, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397–403.
27. Yip GWK, Wang M, Wang T, Chan S, Fung JW, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94:573–580.
28. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor CM, Feiker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, On JK, Patel MR, Kim RJ, Tracy NP, Velazquez EJ, Anstrom KJ.
Clinical Phenotypes in Heart Failure with Preserved Ejection

Hernandez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268–1277.

28. Borlaug BA. Heart failure with preserved and reduced ejection fraction: different risk profiles for different diseases. Eur Heart J. 2013;34:1393–1395.

29. Cleland JG, Pellicori P, Dierckx R. Clinical trials in patients with heart failure and preserved left ventricular ejection fraction. Heart Fail Clin. 2014;10:511–523.

30. De Keulenaer GW, Brustaert DL. The heart failure spectrum. Time for a phenotype-oriented approach. Circulation. 2009;119:3044–3046.

31. Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF, Redfield MM. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64:541–549.

32. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, Ghali JK, Liebson PR. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001;104:779–782.

33. Ennezat PV, Le Jemtel TH, Logeart D, Marechaux S. Heart failure with preserved ejection fraction: a systemic disorder? Rev Med Interne. 2012;33:370–380.

34. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259.

35. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–269.

36. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282–2289.

37. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, Marino PK, Lyles M, Cushman M, Enright PL. Cardiorenal Health Study Research Group. Importance of heart failure with preserved systolic function in patients ≥65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001;87:413–419.

38. Banerjee P, Clark AL, Cleland JG. Diastolic heart failure: a difficult problem in the elderly. Am J Geriatr Cardiol. 2004;13:16–21.

39. Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JGF. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol. 2002;39:138–141.

40. Loffredo FS, Nikolova AP, Pancoast JR, Lee RT. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res. 2014;115:97–107.

41. Jei W. Mechanisms of disease: age and the cardiovascular system. N Engl J Med. 1992;327:1735–1739.

42. Nilsson PM. Hemodynamic aging as the consequence of structural changes associated with early vascular aging (EVA). Circulation. 2014;131:112–119.

43. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffening in patients with heart failure and preserved ejection fraction: a systemic disorder? Circulation. 2006;114:2254–2262.

44. Kaeser GA, Hauer J, Bähr E, Schmaus M, Wieland T, Widimsky J, Menger MD, Lin F, Schaper F, Kilchenmann J, et al. Adverse cardiac remodeling in patients with heart failure and preserved ejection fraction: a RELAX trial ancillary study. Circulation. 2005;112:2254–2262.

45. Hart CY, Meyer DM, Tazelaar HD, Grande JP, Burnett JC Jr, Housmans PR, Redfield MM. Load versus humoral activation in the genesis of early diastolic heart failure. Circulation. 2001;104:215–220.

46. Najjar SS, Schulman SP, Gerstenblith G, Fleg JL, Kas DA, O’Connor F, Becker LC, Lakatta EG. Age and gender affect ventricular-vascular coupling during aerobic exercise. J Am Coll Cardiol. 2004;44:611–617.

47. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:18–28.

48. Gradman AH, Afiyouni F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis. 2006;48:326–341.

49. Zile MR, Gaasch WH, Patel K, Aban IB, Ahmed A. Adverse left ventricular remodeling in community-dwelling older adults predicts incident heart failure and mortality. JACC Heart Fail. 2012;2:512–522.

50. Vogel MW, Slusser JP, Hodge DO, Chen HH. The natural history of preclinical diastolic dysfunction: a population-based study. Circ Heart Fail. 2012;5:144–151.

51. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta Stone. J Am Coll Cardiol. 1997;30:8–18.

52. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271.

53. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840–844.
Clinical Phenotypes in Heart Failure with Preserved Ejection

Samson et al

DOI: 10.1161/JAHA.115.002477

106. Regnau V, Thomas F, Safar ME, Osborne-Pellegrin M, Khalil RA, Pannier B, Lacolley P. Sex differences in cardiovascular risk: role of pulse pressure amplification. J Am Coll Cardiol. 2012;59:1771–1777.

107. Coutinho T, Borlaug BA, Pelikka PA, Turner ST, Kullo II. Sex differences in arterial stiffness and ventricular-arterial interactions. J Am Coll Cardiol. 2013;61:99–103.

108. Kenaclsha S, Evans JP, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med. 2007;357:305–313.

109. Peterson LR, Waggoner AD, Schectman KB, Meyer T, Gropler RJ, Barzilai B, Davila-Roman VG. Alterations in left ventricular structure and function in young, healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol. 2004;43:1399–1404.

110. Wong CY, O’Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation. 2004;110:3081–3087.

111. Kishi S, Armstrong AC, Gidding SS, Colangelo LA, Venkatesh BA, Jacobs DR Jr, Carr JJ, Terry JP, Liu K, Goff DC Jr, Lima JA. Association of obesity in early adulthood and metabolic syndrome with incident left ventricular dysfunction and structural remodeling: the CARDIA study (Coronary Artery Risk Development in Young Adults). JACC Cardiovasc Imaging. 2014;7:222–230.

112. Khandheria BK, Somers VK, Khandheria BK, Khandheria BK, Somers VK. Comparison of cardiac structure and function in obese vs non-obese young adults. JACC Cardiovasc Imaging. 2013;6:789–795.

113. Shah R, Gayat E, Januzzi Jr, Sr, Noto S, Cohen-Solal A, Noto S, Cohen-Solal A. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension. 2001;38:423–437.

114. Wildman RP, Mackey RH, Bostom A, Thompson T, Sutton-Tyrrell K. Measures of obesity are associated with vascular stiffness in young and older adults. Hypertension. 2003;42:468–473.

115. Weisbrod RM, Shiang T, Al Sayah L, Fry JL, Bajpai S, Reinhart-King CA, Lob HE, Santhanam L, Mitchell G, Cohen RA, Seta F. Arterial stiffening precedes systolic hypertension in diet-induced obesity. Hypertension. 2013;62:1105–1110.

116. Dengo AL, Dennis EA, Orr JS, Marinik EL, Ehrlich E, Davy BM, Davy KP. Arterial stiffening with weight loss in overweight and obese middle-aged and older adults. Hypertension. 2010;55:855–861.

117. Nordstrand N, Gjevestad E, Hertel JK, Johnson LK, Saltvedt E, Roislien J, Alpert MA, Lambert CR, Panayiotou H, Terry BE, Cohen RA, Seta F. Arterial stiffening precedes systolic hypertension in diet-induced obesity. Hypertension. 2013;62:1105–1110.

118. Alpert MA, Lambert CR, Panayiotou H, Terry BE, Cohen MV, Massy CV, Hashimi MW, Mukherji V. Relation of duration of morbid obesity to left ventricular vascular stiffness, systolic function, and diastolic filling, and effect of weight loss on arterial stiffness. J Am Coll Cardiol. 1995;26:1194–1197.

119. Otto ME, Belohlavek M, Romero-Corral A, Camis AS, Gilman GA, Svatikova A, Amin RS, Lopez-Fernandez J, Khandheria BK, Somers VK. Comparison of cardiac structural and functional changes in obese otherwise healthy adults with versus without obstructive sleep apnea. Am J Cardiol. 2007;99:1298–1302.

120. Fung JW, Li TS, Choy DK, Yip GW, Ko FW, Sanderson JE, Hui DS. Severe obstructive sleep apnea is associated with left ventricular diastolic dysfunction. Chest. 2002;121:422–429.

121. Arias MA, Garcia-Rio F, Alonso-Fernandez A, Mediano O, Martinez I, Villamor I. Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation. 2005;112:375–383.

122. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Flores JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Wu M, Young T. Sleep apnea and an American disease: an American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardioiology, Stroke Council, and Council on Cardiovascular Nursing. American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardioiology, American Heart Association Council on Cardiovascular Nursing. Circulation. 2008;118:1080–1111. Erratum in: Circulation. 2009;119:e380.

123. Vogtanas AN, Tan TL, Bixler EO, Martin LF, Shubert D, Kales A. Sleep apnea and sleep disruption in obese patients. Arch Intern Med. 1994;154:1705–1711.

124. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tilisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2007;50:202–208.

125. Leibman EB, Yang AZ, Wolk A, Mittelmeier MA. Adiposity and incidence of heart failure hospitalization and mortality: a population-based prospective study. Circ Heart Fail. 2009;2:202–208.

126. Shah R, Gayat E, Januzzi Jr, Sr, Noto S, Cohen-Solal A, Subramanian S, Fairman E, Harjola VP, Ishihara S, Lassus J, Maggioni A, Metra M, Mueller C, Mueller T, Parente N, Pascual-Fidalga D, Peacock WF, Spinat J, van Kemenade R, Mebazaa A; GREAT (Global Research on Acute Conditions Team) Network. Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. J Am Coll Cardiol. 2014;63:778–785.

127. Khalid U, Ather S, Baviishi C, Chan W, Loehr LR, Urmson RD, Chang PP, Coresh J, Virani SS, Nambi V, Bozkurt B, Ballantyne CM, Deswal A. Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol. 2014;64:2743–2749.

128. Chrysant SG, Chrysant SG. New insights into the true nature of the obesity paradox and the lower cardiovascular risk. J Am Soc Hypertens. 2013;7:85–94.

129. Bibbins-Domingo K, Fletcher MJ, Lin F, Vittinghoff E, Gardin JM, Aryanchna Y, Lewis CE, Williams OD, Hulley SB. Racial differences in incident heart failure among young adults. Am J Cardiol. 2009;103:1179–1180.

130. Kizer JR, Arnett DK, Bella JN, Paranicas M, Rao DC, Province MA, Oberman A, Vaccarino V, Din-Dzietham R, Gibbons GH, Quyyumi A. Racial differences in prevalence and prognosis in heart failure. J Am Coll Cardiol. 2014;63:1848–1858.

131. Selvin E, Ballantyne CM, Nambi V. Obesity, subclinical myocardial injury, and arterial stiffness and ventricular-arterial interactions. J Am Coll Cardiol. 2013;61:918–926.

132. Komajda M,emez A. Obstructive sleep apnea affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation. 2005;112:375–383.
Clinical Phenotypes in Heart Failure with Preserved Ejection

Samson et al

DOI: 10.1161/JAHA.115.002477

Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, McCullough PA, Ren Fielding C, Franklin BA; American Heart Association Committee of the Council on Nutrition, Physical Activity, and Metabolism. Bariatric surgery to unload the stressed heart. J Am Heart Assoc. 2011;123:1683–1701.

Owan T, Avezal E, Morley K, Jiji R, Hall N, Kreuzovski J, Gallagher J, Williams Z, Preece K, Ngunnong N, Strong MB, Pendleton RC, Segerson N, Cloward TV, Walker JM, Fanney RJ, Gress RE, Adams TD, Hunt SC, Litwin SE. Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah obesity study. J Am Coll Cardiol. 2011;57:732–739.

Leichman JG, Wilson EB, Scarborough T, Aguilar D, Miller CC III, Yu S, Algahim MF, Sen S, Taegtmeyer H. Dramatic reversal of pulmonary hypertension associated with left ventricular diastolic dysfunction. Circulation. 2013;128(15 Suppl 1):H1539–H1545.

Ashrafian H, le Roux CW, Darzi A, Athanasiou T. Effects of bariatric surgery on cardiovascular function. Circulation. 2008;118:2091–2102.

Hooper MM, Barbera JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Peppe-Zaba J, Redfield MM, Robbins IM, Souza R, Torbicki A, McGoon M. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension. J Am Coll Cardiol. 2013;63:585–596.

Guglin M, Khan H. Pulmonary hypertension in heart failure. J Card Fail. 2010;16:461–474.

Haddad F, Kudelko K, Mercier O, Vrtovec B, Zamanian RT, de Jesus Perez V. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis. 2011;54:154–167.

Georgiopoulou VV, Kalogeropoulou AP, Borlaug BA, Gheorghiade M, Butler J. Left ventricular dysfunction with pulmonary hypertension: part 1: epidemiology, pathophysiology, and definitions. Circ Heart Fail. 2013;6:344–354.

Kalogeropoulou AP, Georgiopoulou VV, Borlaug BA, Gheorghiade M, Butler J. Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research. Circ Heart Fail. 2013;6:584–593.

Rich S, Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation. 2008;118:2190–2199.

Hill NS, Preston I, Roberts K. Defining the phenotypes for pulmonary hypertension associated with diastolic heart failure. Circ Heart Fail. 2011;4:238–240.

Enriquez-Sarano M, Rossi A, Seward JB, Bailey KR, Tajik AJ. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol. 1997;29:153–159.

Robbins JD, Maniari PB, Cotts W, Parker MA, Bonow RO, Gheorghiade M. Prevalence and severity of functional mitral regurgitation in chronic systolic heart failure. Am J Cardiol. 2003;91:360–362.

Gerges C, Gerges M, Lang MB, Zhang Y, Jakowitsch J, Probst P, Maurer G, Lang IM. Diastolic pulmonary vascular pressure gradient: a predictor of “out-of-proportion” pulmonary hypertension. Chest. 2013;143:758–766.

Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8–17.

Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555–1562.

Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361:1864–1871.

Lam CS, Rosebrugh RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119–1126.

Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, Rich S. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2011;4:257–265.

Perez VA, Haddad F, Zamanian RT. Diagnosis and management of pulmonary hypertension associated with left ventricular diastolic dysfunction. Pulm Circ. 2012;2:163–169.

Maréchaux S, Neicu DV, Braun S, Richardson M, Delsart P, Bouabdallahu N, Banfi C, Gautier C, Graux P, Asseman P, Pibarot P, Le Jemtel TH, Ennezat PV. Lille HPPP Study Group. Functional mitral regurgitation: a link to pulmonary hypertension in heart failure with preserved ejection fraction. J Card Fail. 2011;17:806–812.

Ennezat PV, Maréchaux S, Pibarot P, Le Jemtel TH. Secondary mitral regurgitation in heart failure with reduced or preserved left ventricular ejection fraction. Cardiology. 2013;125:110–117.

Maréchaux S, Pinçon C, Poueymierandette M, Verhaeghe M, Bellouin A, Asseman P, Le Tourneau T, Lejeunet TH, Pibarot P, Ennezat PV. Elevated left atrial pressure estimated by Doppler echocardiography is a key determinant of mitral valve toning in functional mitral regurgitation. Heart. 2010;96:289–297.

Maréchaux S, Terrade J, Biausque F, Letefy Z, Deturck R, Asseman P, Le Jemtel TH, Ennezat PV. Exercise-induced functional mitral regurgitation in heart failure and preserved ejection fraction: a new entity. Eur J Echocardiogr. 2010;11:E14.

Ennezat PV, Maréchaux S, Bouabdallahu N, Le Jemtel TH. Dynamic nature of pulmonary arterial systolic pressure in decompensated heart failure with preserved ejection fraction: role of functional mitral regurgitation. J Card Fail. 2013;19:746–752.

Willems HJ, Kessler KM. Severe pulmonary hypertension associated with diastolic left ventricular dysfunction. Chest. 1993;103:1877–1883.

Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest. 2009;136:37–43.

Guazzi M, Gomberg-Maitland M, Arena R. Pulmonary hypertension in heart failure with preserved ejection fraction. J Heart Lung Transplant. 2015;34:273–281.

Robbins IM, Hennes AR, Pugh ME, Brittain EL, Zhao DX, Plana RN, Fong PP, Newman JH. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail. 2014;7:116–122.

Andersen MJ, Olson TP, Melenovsky V, Kane GC, Borlaug BA. Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure. Circ Heart Fail. 2015;8:41–48.

Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588–595.

Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HH, Merlini G. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451–2466.

Westermann D, Becher PM, Lindner D, Savatiss K, Xia Y, Fröhlich M, Hoffmann S, Schultheiss HP, Tschöpe C. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol. 2012;107:308.

Testani JM, St John Sutton MG, Wiegors SE, Khera AV, Shannon RP, Kirkpatrick JH. Accuracy of noninvasively determined pulmonary artery systolic pressure. J Am Coll Cardiol. 2010;55:1192–1197.

Attaran RR, Ramaraj R, Sorrell VL, Movahed MR. Poor correlation of estimated pulmonary artery systolic pressure between echocardiography and right heart catheterization in patients awaiting cardiac transplantation: results from the clinical arena. Transplant Proc. 2009;41:3827–3830.

Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015;36:2565–2573.

Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164–174.
185. Kanwar M, Tedford RJ, Agarwal R, Clarke MM, Walter C, Sokos G, Murali S, Bennett NL. Management of pulmonary hypertension due to heart failure with preserved ejection fraction. *Curr Hypertens Rep.* 2014;16:501.

186. Ohara T, Ohte N, Little WC. Pulmonary hypertension in heart failure with reduced ejection fraction: a target for therapy? *Circulation.* 2011;124:133–135.

187. Bonderman D, Ghi G, Fels SB, Ghofrani HA, Michelakis E, Mitrovic V, Oudj D, Rottiers AV, Ressing L, Sensenbrenner MJ. Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension: Riociguat Trial (LEPHT) Study Group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. *Circulation.* 2013;128:502–511.

188. Burch GE, Tsui CY, Harb JM. Ischemic cardiomyopathy. *194. Ohara T, Little WC. Evolving focus on diastolic dysfunction in patients with heart failure and normal left ventricular ejection fraction. Circulation.* 2011;124:292–300.

189. Kanwar M, Tedford RJ, Agarwal R, Clarke MM, Walter C, Sokos G, Murali S, Bennett NL. Management of pulmonary hypertension due to heart failure with preserved ejection fraction. *Curr Hypertens Rep.* 2014;16:501.

190. Burch GE, Tsui CY, Harb JM. Ischemic cardiomyopathy. *Am Heart J.* 1989;117:146–150.

191. Raftery EB, Banks DC, Oram S. Oclusive disease of the coronary arteries presenting as primary congestive cardiomyopathy. *Lancet.* 1969;2:1146–1150.

192. Burch GE, Tsui CY, Harb JM. Ischemic cardiomyopathy. *Am Heart J.* 1989;117:146–150.

193. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. *N Engl J Med.* 2003;344:1481–1489.

194. Ohara T, Ohte N, Little WC. Pulmonary hypertension in heart failure with reduced ejection fraction: a target for therapy? *Circulation.* 2011;124:133–135.

195. Bonderman D, Ghi G, Fels SB, Ghofrani HA, Michelakis E, Mitrovic V, Oudj D, Rottiers AV, Ressing L, Sensenbrenner MJ. Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension: Riociguat Trial (LEPHT) Study Group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. *Circulation.* 2013;128:502–511.

196. Wijns W, Serruys PW, Slager CJ, Grimm J, Krayenbuehl HP, Hugenholtz PG, et al. Percutaneous coronary intervention for coronary artery disease. *Circulation.* 1993;87:1146–1150.

197. Argulian E, Halpern DG, Agarwal V, Agarwal SK, Chaudhry FA. Predictors of death in a predominantly male population with heart failure and preserved versus reduced ejection fraction. *J Am Coll Cardiol.* 2012;59:998–1005.

198. Maréchaux S, Six-Carpentier M, Bouabdallah M, Montaigne D, Bauchart JJ, Mouquet F, Auffray JL, Le Tourneau T, Asseman P, Lejeunet LM, Enneazt PV. Prognostic importance of comorbidities in heart failure with preserved left ventricular ejection fraction. *Heart Vessels.* 2011;26:313–320.

199. Lund LH, Donal E, Oger E, Hage C, Persson H, Haugen-Lofman I, Enneazt PV, Sportouch-Dukhan C, Drouet E, Daubert JC, Linde C, Kønig Investigators. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. *Eur J Heart Fail.* 2014;16:992–1001.

200. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Nieffel M, Herbert R, Wu AW. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. *J Am Coll Cardiol.* 2003;42:1226–1233.

201. Grigorian-Shamanian L, Otero Ravina F, Abu Assi E, Vidal Perez T, Teijera-Fernandez E, Varela A, Moreira Sayages L, Gonzalez-Juantejery WT. Why do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. *Am Heart J.* 2008;156:1184–1190.

202. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKeilre V, Platszyńska A, Hettel SJ, Massie BM, Carson PE; I-Preserve Investigators. Mode of death in patients with heart failure and preserved ejection fraction: results from the I-preserve in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. *Circulation.* 2010;121:1393–1405.

203. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. *Circ Heart Fail.* 2008;1:91–97.

204. Magnani JW, Rienstra M, Lin H, Sinner MF, Lubitz SA, McManus DD, Dupuis J, Ellenor PT, Benjamin EJ. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. *Circulation.* 2011;124:1982–1993.

205. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKeilre VS, Komajda M, McMurray JJ, Lindenfeld J, Kao DP. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. *Eur J Heart Fail.* 2015;17:925–935.

206. Magni AG, Dahlström U, Filipatios C, Chioncel O, Leiro MC, Drozd J, Frühwald F, Gillestad L, Logeat D, Fabbi G, Urho R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L. EURObservational Research Programme: regional differences and year-follow-up results of the heart failure pilot survey (ESC-HF Pilot). *Eur J Heart Fail.* 2013;15:808–817.

207. Seiler J, Stevenson WG. Atrial fibrillation in congestive heart failure. *Cardiol Rev.* 2010;18:38–50.

208. Rusinaru D, Leborgne L, Pettier M, Tribouilloy C. Effect of atrial fibrillation on long-term survival in patients hospitalised for heart failure with preserved ejection fraction. *Eur J Heart Fail.* 2008;10:556–572.

209. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoudbadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. *Eur J Heart Fail.* 2009;11:674–683.
Clinical Phenotypes in Heart Failure with Preserved Ejection fraction

Samson et al

DOI: 10.1161/JAHA.115.002477

Journal of the American Heart Association

CONTEMPORARY REVIEW
Clinical Phenotypes in Heart Failure with Preserved Ejection Samson et al

270. Butt M, Dwivedi G, Shantsila A, Khair OA, Lip GY. Left ventricular systolic and diastolic dysfunction in obstructive sleep apnea: impact of continuous positive airway pressure therapy. Circ Heart Fail. 2012;5:226–233.

271. Marin JM, Agusti A, Villar I, Forner M, Nieto D, Carrijo SJ, Barbe F, Vicente E, Wei Y, Nieto FJ, Jelic S. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA. 2012;307:2169–2176.

272. Chirinos JA, Gurubhagavatula I, Teff K, Rader DJ, Wadden TA, Townsend R, Foster GD, Maislin G, Shantsila A, Khair OA, Lip GY. Left ventricular systolic and diastolic dysfunction in obesity with obstructive sleep apnea: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med. 2007;167:757–764.

273. Haentjens P, Van Meerhaeghe A, Moscariello A, De Weerdt S, Poppe K, Dupont A, Velkeniers B. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: a unifying hypothesis. Hypertens Res. 2008;31:1865–1872.

274. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction: a population-based study. J Am Coll Cardiol. 2010;55:300–305.

275. Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B. Comparison of diabetes mellitus among those with versus without diabetes mellitus. Am J Cardiol. 2008;105:373–378.

276. Tribouilloy C, Rusinaru D, Mahjoub H, Tartiere JM, Kesri-Tartiere L, Godard S, Pelletier M. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study. Heart. 2008;94:1450–1455.

277. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ; CHARM Investigators. Impact of diabetes on outcomes in patients with low ejection fraction. Eur Heart J. 2010;31:1865–1872.

278. Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, Ciaggett B, Shah AM, Santos AB, Zile MR, Voors AA, McMurray JJ, Packer M, Bransford T, Lefkowitz M, Solomon SD; PARAMOUNT Investigators. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3442–3451.

279. Katz DH, Burns JA, Aguilar FG, Beussink L, Shah SJ, Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction. JACC Heart Fail. 2014;2:586–596.

280. Rusinaru D, Buicic O, Houpe D, Tribouilloy C. Renal function and long-term survival after hospital discharge in heart failure with preserved ejection fraction. Int J Cardiol. 2011;147:278–282.

281. Damman K, Perez AC, Anand IS, Komajda M, McKelvie RS, Zile MR, Massie B, Carson PE, McMurray JJ. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol. 2014;64:1106–1113.

282. Tibbs AS, Ennezat PV, Chen JA, Haider A, Gundewar S, Cotlaran V, Aggarwal VS, Taleja A, Le Jemtel TH. Diabetes lowers aerobic capacity in heart failure. J Am Coll Cardiol. 2005;45:930–931.

283. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107:3040–3046.

284. Nishio M, Sakata Y, Mano T, Ohtani T, Takeda Y, Hori M, Yamamoto K. Difference of clinical characteristics between hypertensive patients with and without diastolic heart failure: the roles of diastolic dysfunction and renal insufficiency. JACC Heart Fail. 2013;6:733–739.

Key Words: Aging • heart failure • hypertension • obesity • preserved ejection fraction